Keryx Biopharmaceuticals Inc. (KERX)
-NasdaqCM 8.24 
0.58(7.57%) 4:00PM EDT|After Hours
:
8.15 0.09 (1.09%) 4:41PM EDT
| Prev Close: | 7.66 |
|---|
| Open: | 8.05 |
|---|
| Bid: | 8.02 x 1000 |
|---|
| Ask: | 8.37 x 600 |
|---|
| 1y Target Est: | 13.22 |
|---|
| Beta: | 3.67 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 8.02 - 8.50 |
|---|
| 52wk Range: | 1.68 - 9.98 |
|---|
| Volume: | 9,269,789 |
|---|
| Avg Vol (3m): | 2,436,850 |
|---|
| Market Cap: | 673.36M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Movers roundup: DreamWorks Animation, KeryxAP(Wed 2:45PM EDT)
- Keryx shares rise on analyst's Zerenex forecastAP(Wed 1:52PM EDT)
- 3 Biotechs With Strong Momentum - Can They Keep It Up?at Seeking Alpha(Wed 1:40PM EDT)
- Keryx Patents Seen Overcoming Generic Competitionat Investor's Business Daily(Wed 12:39PM EDT)
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andEDGAR Online(Thu, Jun 13)
- Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)at TheStreet(Tue, Jun 11)
- Biotech Stock Mailbag: 2013 Clinical Trials Calendarat TheStreet(Fri, Jun 7)
- Solid Showing At WCN Conference For Keryx: Catalysts Still To Comeat Seeking Alpha(Tue, Jun 4)
- KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial SEDGAR Online(Tue, Jun 4)
- Clovis Among Top Small-Cap Biotech Picks By Legendary Fund Managers In Q1/2013at Seeking Alpha(Tue, Jun 4)
- Keryx announces positive Zerenex Phase 3 datatheflyonthewall.com(Mon, Jun 3)
- Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of NephrologyPR Newswire(Mon, Jun 3)
- Here's What This $42 Billion Hedge Fund Company Has Been Buyingat Motley Fool(Thu, May 30)
- Keryx: Attractive In Front Of Catalyst-Rich Second Halfat Seeking Alpha(Thu, May 30)
Press Releases
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of NephrologyPR Newswire(Mon, Jun 3)
- Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial ResultsPR Newswire(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | 117.71 |
|---|
| P/S (ttm): | 89.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.32 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.80 |
|---|
Business Summary
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
View More